• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Dabigatran etexilate: a new oral thrombin inhibitor.

作者信息

Hankey Graeme J, Eikelboom John W

机构信息

Department of Neurology, Royal Perth Hospital, 197 Wellington St, Perth, Australia 6001.

出版信息

Circulation. 2011 Apr 5;123(13):1436-50. doi: 10.1161/CIRCULATIONAHA.110.004424.

DOI:10.1161/CIRCULATIONAHA.110.004424
PMID:21464059
Abstract
摘要

相似文献

1
Dabigatran etexilate: a new oral thrombin inhibitor.达比加群酯：一种新型口服凝血酶抑制剂。
Circulation. 2011 Apr 5;123(13):1436-50. doi: 10.1161/CIRCULATIONAHA.110.004424.
2
Dabigatran etexilate (Pradaxa)--a new oral anticoagulant.达比加群酯（Pradaxa）——一种新型口服抗凝剂。
Med Lett Drugs Ther. 2010 Nov 15;52(1351):89-90.
3
Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin.达比加群酯：一种新型口服有效的可逆的非肽类凝血酶抑制剂。
Arterioscler Thromb Vasc Biol. 2010 Oct;30(10):1885-9. doi: 10.1161/ATVBAHA.110.203604. Epub 2010 Jul 29.
4
Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor.达比加群酯的药理学、药代动力学和药效学：一种口服直接凝血酶抑制剂。
Clin Appl Thromb Hemost. 2009 Sep-Oct;15 Suppl 1:9S-16S. doi: 10.1177/1076029609343004. Epub 2009 Aug 19.
5
[Dabigatran: a new therapeutic option for therapy and prophylaxis of thromboembolic diseases?].达比加群：血栓栓塞性疾病治疗与预防的一种新治疗选择？
Dtsch Med Wochenschr. 2010 Feb;135(6):256-9. doi: 10.1055/s-0030-1247864. Epub 2010 Jan 26.
6
A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: THE Randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN).比较达比加群酯与华法林在机械心脏瓣膜患者中的应用：THE 随机、Ⅱ期研究，评估心脏瓣膜置换术后口服达比加群酯的安全性和药代动力学（RE-ALIGN）。
Am Heart J. 2012 Jun;163(6):931-937.e1. doi: 10.1016/j.ahj.2012.03.011.
7
Dabigatran etexilate: pivotal trials for venous thromboembolism prophylaxis after hip or knee arthroplasty.达比加群酯：髋关节或膝关节置换术后静脉血栓栓塞预防的关键试验。
Clin Appl Thromb Hemost. 2009 Sep-Oct;15 Suppl 1:25S-31S. doi: 10.1177/1076029609340668. Epub 2009 Jul 31.
8
Dabigatran etexilate for the prophylaxis of venous thromboembolism after hip or knee replacement rationale for dose regimen.达比加群酯预防髋或膝关节置换术后静脉血栓栓塞的剂量方案：原理。
Clin Appl Thromb Hemost. 2009 Sep-Oct;15 Suppl 1:17S-24S. doi: 10.1177/1076029609344588. Epub 2009 Aug 19.
9
Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment.口服直接凝血酶抑制剂达比加群酯的药代动力学和药效学不受中度肝功能损害的影响。
J Clin Pharmacol. 2008 Dec;48(12):1411-9. doi: 10.1177/0091270008324179. Epub 2008 Sep 30.
10
Dabigatran etexilate: future directions in anticoagulant treatment.达比加群酯：抗凝治疗的未来方向。
Clin Appl Thromb Hemost. 2009 Sep-Oct;15 Suppl 1:32S-41S. doi: 10.1177/1076029609344199. Epub 2009 Aug 13.

引用本文的文献

1
Salvianolic acid B inhibits thrombosis and directly blocks the thrombin catalytic site.丹酚酸B抑制血栓形成并直接阻断凝血酶催化位点。
Res Pract Thromb Haemost. 2024 May 17;8(4):102443. doi: 10.1016/j.rpth.2024.102443. eCollection 2024 May.
2
Optimizing antithrombotic therapy in patients with coexisting cardiovascular and gastrointestinal disease.优化合并心血管疾病和胃肠道疾病患者的抗栓治疗
Nat Rev Cardiol. 2024 Aug;21(8):574-592. doi: 10.1038/s41569-024-01003-3. Epub 2024 Mar 20.
3
Cardiac Tamponade and Duodenal Hemorrhage Caused by Inappropriate Use of Dabigatran in a Patient With End-Stage Renal Failure: A Case Report.
终末期肾衰竭患者不当使用达比加群导致心脏压塞和十二指肠出血：一例报告
Cureus. 2024 Jan 18;16(1):e52521. doi: 10.7759/cureus.52521. eCollection 2024 Jan.
4
Head-to-head ex vivo comparison of clinically used direct anticoagulant drugs.临床使用的直接抗凝药物的体外直接比较
Naunyn Schmiedebergs Arch Pharmacol. 2024 Jun;397(6):4461-4470. doi: 10.1007/s00210-023-02891-x. Epub 2023 Dec 19.
5
Optimal management of cardiac surgery patients using direct oral anticoagulants: recommendations for clinical practice.心脏外科手术患者使用直接口服抗凝剂的最佳管理：临床实践建议。
Eur J Cardiothorac Surg. 2023 Oct 4;64(4). doi: 10.1093/ejcts/ezad340.
6
Preliminary findings on left atrial appendage occlusion simulations applying different endocardial devices.应用不同心内膜装置进行左心耳封堵模拟的初步研究结果。
Front Cardiovasc Med. 2023 Feb 20;10:1067964. doi: 10.3389/fcvm.2023.1067964. eCollection 2023.
7
Anticoagulation Holiday: Resumption of Direct Oral Anticoagulants for Atrial Fibrillation in Patients with Index Traumatic Intracranial Hemorrhage.抗凝假期：创伤性颅内出血患者房颤患者直接口服抗凝剂的恢复使用
World Neurosurg X. 2022 Oct 12;17:100148. doi: 10.1016/j.wnsx.2022.100148. eCollection 2023 Jan.
8
Effects of dabigatran versus warfarin on 2-year cognitive outcomes in old patients with atrial fibrillation: results from the GIRAF randomized clinical trial.达比加群酯与华法林对老年心房颤动患者 2 年认知结局的影响：来自 GIRAF 随机临床试验的结果。
BMC Med. 2022 Oct 26;20(1):374. doi: 10.1186/s12916-022-02563-2.
9
Warfarin resistance: possibilities to solve this problem. A case report.华法林抵抗：解决这个问题的可能性。病例报告。
J Int Med Res. 2022 Jun;50(6):3000605221103959. doi: 10.1177/03000605221103959.
10
Oral anticoagulation versus antiplatelet therapy for secondary stroke prevention in patients with embolic stroke of undetermined source: A systematic review and meta-analysis.口服抗凝治疗与抗血小板治疗用于不明来源栓塞性卒中患者二级预防的系统评价和荟萃分析
Eur Stroke J. 2022 Jun;7(2):92-98. doi: 10.1177/23969873221076971. Epub 2022 Feb 11.